Clinical Trials Directory

Trials / Completed

CompletedNCT02704728

Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
18 (actual)
Sponsor
4D pharma plc · Industry
Sex
All
Age
16 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of Bacteroides thetaiotaomicron (Thetanix®)) capsules in young people aged 16 to 18 years with stable Crohn's disease.

Detailed description

This study is a single (Part A) and multiple (Part B) dose study. Following informed consent and screening, 10 eligible subjects will receive a single dose of Thetanix or placebo in the clinic. A Safety Review Committee will review the safety data up to Day 7 from these first ten subjects and determine if it is appropriate to continue into Part B in which 10 subjects will receive 15 doses of Thetanix or placebo in a twice daily dosing regimen over 7.5 days. In both parts of the study, 8 of the 10 subjects will randomly receive Thetanix and 2 subjects will randomly receive placebo. Each dose consists of three capsules. Subjects in Part B will receive the first and last dose in the clinic and will take 13 doses at home. While at home, subjects will be required to answer questions about their health, record their body temperature and when they take the capsules in an electronic diary. Subjects developing a fever will undergo further assessments, including blood cultures. Subjects will provide stool samples for analysis of microbiota and faecal calprotectin.

Conditions

Interventions

TypeNameDescription
OTHERThetanixThetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
OTHERPlaceboPlacebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.

Timeline

Start date
2015-12-01
Primary completion
2018-04-01
Completion
2018-04-01
First posted
2016-03-10
Last updated
2018-06-28

Locations

5 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02704728. Inclusion in this directory is not an endorsement.